Human Immunology Biosciences Stock

www.hibio.comHealthcare / BioTech & PharmaFounded: 2021

Human Immunology Biosciences, or HI-Bio, is a biotechnology company using human genetic and immunological research. With a mission to develop precise therapies for patients with immune-mediated diseases (IMDs), HI-Bio focuses on draining the cellular drivers of these diseases to grow their programs to other IMD indicators through clinical-stage programming and pipeline. Human Immunology Biosciences was founded by Travis Murdoch in 2021 and is headquartered in San Francisco, CA.

Register To Buy and Sell Shares

For more details on private stock price information, financing and valuation for Human Immunology Biosciences, register or login.

Please provide a valid email address.

By registering, you agree to Forge’s Terms of Use. Already registered? Log in

OverviewFinancingsValuation

Enterprise Value

Powered by Forge Data

Access Human Immunology Biosciences’ valuation and stock price.

View secondary pricing information, VWAP and distribution waterfall. And seek potentially outsized returns with same day private market data for private companies like Human Immunology Biosciences.

Become part of the Secondary Marketplace, catering to both individual and institutional investors.

Access Stock Price

Animation displayed is not current and securities are shown for illustrative purposes only.

Team

Management Team

Travis Murdoch MD
Founder & Chief Executive Officer
Carl Enell
Chief Operating Officer
Christina Carlson J.D.
General Counsel
Uptal Patel M.D.
Chief Medical Officer
Michele Anderson
Senior Vice President, Regulatory Affairs
Lorna Dean
Senior Vice President, Development Operations

Board Members

Barbara Krebs-Pohl Ph.D.
MorphoSys
Carol Suh
ARCH Venture Partners
Chris Dimitropoulos
Alpha Wave Global
Rachel Mears JD
Jeito
Fred Cohen MD, D.Phil.
Monograph Capital
Paul Berns
ARCH Venture Partners

Human Immunology Biosciences stock FAQs

plusminus

Can you buy Human Immunology Biosciences stock?

As Human Immunology Biosciences is not publicly traded, purchasing its stock is not available to everyone. To buy the stock of a private company like Human Immunology Biosciences, you must be an accredited investor. If you meet the accreditation criteria, you can register for Forge’s Secondary Marketplace to buy private market stock. If you are not an accredited investor, discover how to begin the process to potentially qualify for new investment opportunities.
plusminus

How to buy Human Immunology Biosciences stock?

To invest in a private company like Human Immunology Biosciences through Forge, you must first qualify as an accredited investor. (Learn more about the accreditation process.)
  1. Create a free account to access Forge’s marketplace.
  2. Express your interest in specific investments. Within Forge Markets, you will find detailed pricing and financing information for thousands of private companies.
  3. Throughout this process, a dedicated Forge Private Market Specialist will be available to address any questions you may have and to guide you seamlessly through each step of the transaction.
plusminus

Can you sell Human Immunology Biosciences stock?

Yes, you may be able to sell your Human Immunology Biosciences stock, subject to certain conditions. Forge can help you facilitate the sale of your stock in a manner that aligns with your needs and the company's interests. If you are looking for liquidity, register with us today to begin the process. A dedicated Forge Private Market Specialist will be available to address any questions you may have along the way.
plusminus

How to sell Human Immunology Biosciences stock?

If you hold private company shares of - whether as an employee or an early investor - Forge can help you sell them.
  1. Create a free Forge account, this will give you access to Forge’s marketplace and to one of our experienced Private Market Specialist to answer any questions you might have.
  2. Indicate your interest to sell your Human Immunology Biosciences stock on our platform.
  3. Work with your dedicated Private Market Specialist who'll help guide you through every step of the transaction.
plusminus

Is Human Immunology Biosciences a public company?

No, Human Immunology Biosciences is a privately held company and is currently not publicly traded on any stock markets including NYSE or NASDAQ.
plusminus

What is Human Immunology Biosciences’ stock price?

Human Immunology Biosciences is a privately held company and therefore does not have a public stock price. However, you may access Human Immunology Biosciences’ private market stock price with Forge Data.
plusminus

What is Human Immunology Biosciences’ stock ticker symbol?

Human Immunology Biosciences does not have an official ticker symbol because this company is not currently publicly traded.
plusminus

Can institutional investors buy and sell private market stocks?

Yes. As one of the largest trading platform for the private market, Forge helps institutional investors seek liquidity as they buy and sell private stock for their portfolios or their clients. Our private market specialists have decades of experience working with institutional firms. Learn more or register today to get started.
Human Immunology Biosciences (HI-Bio™), a clinical-stage biotechnology company developing targeted therapies for patients with severe immune-mediated diseases (IMDs), today announced the closing of a $95 million Series B financing led by new investor Alpha Wave Global. Viking Global Investors and Arkin Bio Capital participated in the financing, as well as existing investors Jeito Capital and ARCH Venture Partners.
Updated on: Jul 26, 2024

PLEASE READ THESE IMPORTANT LEGAL NOTICES & DISCLOSURES

Public news articles listed on this page have been curated by Forge based on several factors including, but not limited to, product updates, changes in organization structure, funding rounds, third-party valuations, and key personnel changes. Changes to this list of articles can be made at any time without notice and should not be relied upon for investment purposes. Forge does not verify the accuracy of the information contained in public news articles.